MicroPort NeuroScientific
Founded in 2012, and listed in 2022 in HKEX (Stock Code: 2172.HK.), MicroPort NeuroScientific (Formerly known as "MicroPort NeuroTech") has been at the forefront of neurovascular care. Our comprehensive neuro-interventional devices portfolio encompasses three key domains: hemorrhagic stroke, intracranial atherosclerotic disease (ICAD), and acute ischemic stroke (AIS). As of Nov. 2024, our products are utilized in over 3,300 hospitals across China, providing safe and effective stroke solutions to over 420,000 patients to date. In parallel, we are executing a comprehensive global strategy to drive international growth, with 9 products approved for marketing across 23 countries and regions worldwide.
At MicroPort NeuroScientific, our mission is to deliver accessible, top-quality, and comprehensive solutions for stroke patients globally. We are dedicated to pushing the boundaries of neuro-interventional care, aiming for better and longer lives for patients around the world.
MicroPort NeuroScientific is a subsidiary of MicroPort® Scientific. For more information, please visit microport.com.
Our Purpose
We deeply understand our products are directly related to patients’ lives, and even the slightest deviation could cause significant impact. Because of this, we work to relentlessly master every detail of our medical technologies so that patients everywhere can enjoy better and longer lives. That’s our purpose, and it’s how we remain true to our beliefs and committed to the core values we uphold. These principles are essential to the relationships we build with our partners and customers. And it’s evident in every detail of our workday.
Our Values
Our values define us and guide everything we do:
Quality
We relentlessly pursue excellence and are uncompromising where quality is concerned. In all aspects of our businesses, we are passionate in our pursuit of the highest standards and the implementation of a continuous improvement strategy.
Integrity
We strive to meet the highest ethical standards. This guides how we conduct ourselves both internally and externally with our customers. Keeping this principle in mind in every interaction allows us to have both respect for as well as a positive impact on the world around us.
Innovation
We demonstrate imagination and a pioneering spirit that makes MicroPort® a leading innovator in our industry. Our insights and knowledge are quickly and efficiently applied to maximize physician and patient benefits
Dedication
Hard work, perseverance, and commitment are the underlying characteristics that help us overcome barriers and deliver our robust solutions to the world. We devote our energy to constantly improving our work and recognize that there are no shortcuts to success.
We pride ourselves on our relentless pursuit of innovation. Our R&D teams in Shanghai and around the world work tirelessly to develop products that address the unmet needs of physicians and patients. Our Bridge™ Drug-eluting Stent and Tubridge™ Flow Diverter are prime examples of our commitment to pioneering new technologies that enhance patient care.
Innovation and Excellence
Global Presence
MicroPort NeuroScientific has a strong international presence, with products available in 30+ countries across Europe, the Americas, LATAM, and Asia. Our participation in global conferences like LINNC Paris and SNF-ALICE, along with our collaborative efforts with leading medical institutions, underscores our dedication to sharing knowledge and advancing neurointerventional practices worldwide.
Commitment to Quality
Quality is at the core of everything we do. From product development to clinical application, we adhere to the highest standards to ensure that our devices are safe, effective, and reliable. Our recent inclusion in Shanghai's “Specialized and Sophisticated Enterprises 2024” list is a testament to our brand value, market share, innovation ability, and social contributions.
Collaborative Efforts
We believe in the power of collaboration. By working closely with leading experts and institutions, we are able to bring cutting-edge solutions to market and continuously improve our offerings. Our partnerships, such as the one with Fudan University for the development of the PCAR system, exemplify our commitment to combining engineering and medicine for better patient outcomes.
